Risk: Benefit assessment of old medicines

Research output: Contribution to journalArticlepeer-review


Any meaningful discussion about the present value of old drugs requires appropriate comparisons with new drugs. While there is noisy propaganda claiming the superiority of new drugs, the evidence supporting these claims is often scanty and poor. Therefore, the database utilizable to evaluate old and new drugs is incomplete and fragile. There are several reasons, including the poor dossiers presented for the approval of new drugs, the lack of comparisons aimed at showing superiority of new drugs, the bias frequently involved in clinical trials and the conflict of interests. This brief discussion reviews these questions and gives some examples by comparing diuretics and new antihypertensive agents, ticlopidine and clopidogrel, and atypical and classical antipsychotic agents.

Original languageEnglish
Pages (from-to)581-586
Number of pages6
JournalBritish Journal of Clinical Pharmacology
Issue number6
Publication statusPublished - Dec 2004


  • Antihypertensive drugs
  • Antiplatelet drugs
  • Bias in clinical trials
  • Combined endpoints
  • Comparators
  • Surrogate endpoints

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Risk: Benefit assessment of old medicines'. Together they form a unique fingerprint.

Cite this